September 15, 2023 Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia Approval is for use in myelofibrosis patients with anemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease, and over 30% will discontinue […]
Polycythemia Vera Exercise Recommendations
Abstract Background Exercise therapy during cancer treatment reduces symptom burden and improves quality of life (QoL). Polycythemia vera (PV) is a myeloproliferative neoplasia associated with good overall survival (up to decades) but a significant symptom burden, including thromboembolic events and dysesthesias. There are no specific exercise recommendations for patients with PV. Thus, we aimed to […]
How should we define disease modification in MPN?
by David Wallace A disease modifying drug for MPN patients specifically targets disease-initiating stem cells that lead to MPN phenotypes, leading to regression of the disease while improving associated complications. Our guest MPN expert is Dr. Ghaith Abu-Zeinah from Weill Cornell Medicine in NYC. Listen in to learn more.
MPN Self Advocacy and Education: A Chat with David Wallace
PV Reporter and MPN Cancer Connection founder David Wallace is interviewed on “PV Pod: Stories from the Marrow.” In the newly released podcast, we shed light on MPN self-advocacy and education on myeloproliferative neoplasms. Helpful tips from the podcast: “It’s normal to be depressed and angry about the situation. I think seeking help is very […]
Observational Study Reveals Differences between Aquagenic and Non-aquagenic Itching in MPNs
Abstract Background Pruritus is a frequent symptom experienced by patients with myeloproliferative neoplasms (MPN). Aquagenic pruritus (AP) is the most common type. The Myeloproliferative Neoplasm-Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) self-report questionnaires were distributed to MPN patients before consultations. Objectives The aim of this study was to assess clinical incidence (phenotypical evolution and […]
FDA Extends Review Period for GSK’s Momelotinib
Today, GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration (FDA) has extended the review period of the New Drug Application (NDA) for momelotinib by an additional three months to allow for the evaluation of newly submitted data. The revised completion date is now set for 16th September 2023. Despite this […]
MPN’s and Alzheimer’s: Is there a connection?
by David Wallace and Lou Ann Donovan Chronic inflammation is increasingly understood as a significant factor in the progression of many diseases, including Alzheimer’s and myeloproliferative neoplasms (MPNs), a group of blood cancers[1][2]. Myeloid blood cells, which are overproduced in MPNs, have been associated with Alzheimer’s disease, suggesting a link between these conditions[3]. Emerging evidence […]
Phase 3 Clinical Trial for Polycythemia Vera
Unfortunately for some polycythemia vera (PV) patients, current treatment options may not be fully effective or well-tolerated and may cause serious side effects. But a promising investigational treatment is currently being clinically evaluated. Rusfertide, also known as PTG-300, is an investigational new drug designed to slow the release of iron into the bone marrow. The […]
Transforming MPN Research Through Personal Experience
Part 1 in our new “Rising Stars” series featuring – Dr. Tyler Parsons Written by Heidi Cascarano and David Wallace Early Blood Clot Mysteries Like many MPN patients, Tyler’s journey to diagnosis was a long and winding road, marked by mysterious symptoms that remained unexplained for years. For Tyler, these symptoms took the form of […]
Promising New Gene Target to Combat Blood Cancer
A group of biomedical researchers from around the world, including Dr. Alexander Bick at Vanderbilt University Medical Center, have developed a new technique called PACER to measure the growth rate of abnormal blood stem cells. This breakthrough could help doctors reduce their patients future risk of blood cancer. Why This Matters: The Importance of Understanding […]
- 1
- 2
- 3
- …
- 19
- Next Page »
